Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Oleuropein modulates glioblastoma miRNA pattern different from Olea europaea leaf extract.

Tezcan G, Aksoy SA, Tunca B, Bekar A, Mutlu M, Cecener G, Egeli U, Kocaeli H, Demirci H, Taskapilioglu MO.

Hum Exp Toxicol. 2019 Jun 6:960327119855123. doi: 10.1177/0960327119855123. [Epub ahead of print]

PMID:
31169033
2.

Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation the Therapeutic Efficacy In Vitro.

Eskiler GG, Cecener G, Dikmen G, Egeli U, Tunca B.

Curr Drug Deliv. 2019 May 14. doi: 10.2174/1567201816666190515105532. [Epub ahead of print]

PMID:
31113350
3.

Overexpression of miR-21 Is Associated With Recurrence in Patients With Hepatitis B Virus-Mediated Hepatocellular Carcinoma Undergoing Liver Transplantation.

Dundar HZ, Aksoy F, Aksoy SA, Tasar P, Ugras N, Tunca B, Egeli U, Cecener G, Yerci O, Kaya E.

Transplant Proc. 2019 May;51(4):1157-1161. doi: 10.1016/j.transproceed.2019.01.089. Epub 2019 Feb 8.

PMID:
31101191
4.

Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.

Yurdacan B, Egeli U, Guney Eskiler G, Eryilmaz IE, Cecener G, Tunca B.

J Pharm Pharmacol. 2019 Jul;71(7):1119-1132. doi: 10.1111/jphp.13097. Epub 2019 Apr 25.

PMID:
31025377
5.

Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor-positive breast and prostate cancer cells.

Guney Eskiler G, Eryilmaz IE, Yurdacan B, Egeli U, Cecener G, Tunca B.

J Biochem Mol Toxicol. 2019 Apr 12:e22338. doi: 10.1002/jbt.22338. [Epub ahead of print]

PMID:
30980508
6.

BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.

Guney Eskiler G, Cecener G, Egeli U, Tunca B.

J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.

PMID:
30672063
7.

RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.

Eryilmaz IE, Aytac Vuruskan B, Kaygısız O, Egeli U, Tunca B, Kordan Y, Cecener G.

Prostate. 2019 Feb;79(2):195-205. doi: 10.1002/pros.23724. Epub 2018 Oct 7.

PMID:
30294801
8.

Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.

Guney Eskiler G, Cecener G, Egeli U, Tunca B.

Pharm Res. 2018 Sep 25;35(11):218. doi: 10.1007/s11095-018-2502-6.

PMID:
30255456
9.

Prediction of breast cancer metastasis risk using circulating tumor markers: A follow-up study.

Cetintas S, Tezcan G, Tunca B, Egeli U, Gokgoz MS, Cecener G.

Bosn J Basic Med Sci. 2019 May 20;19(2):172-179. doi: 10.17305/bjbms.2018.3371.

10.

In vitro cytotoxic and antiproliferative effects of usnic acid on hormone-dependent breast and prostate cancer cells.

Eryilmaz IE, Guney Eskiler G, Egeli U, Yurdacan B, Cecener G, Tunca B.

J Biochem Mol Toxicol. 2018 Oct;32(10):e22208. doi: 10.1002/jbt.22208. Epub 2018 Aug 13.

PMID:
30101414
11.

The role of usnic acid-induced apoptosis and autophagy in hepatocellular carcinoma.

Yurdacan B, Egeli U, Eskiler GG, Eryilmaz IE, Cecener G, Tunca B.

Hum Exp Toxicol. 2019 Feb;38(2):201-215. doi: 10.1177/0960327118792052. Epub 2018 Aug 7.

PMID:
30084279
12.

Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer.

Guney Eskiler G, Cecener G, Dikmen G, Egeli U, Tunca B.

Eur J Pharm Sci. 2018 Jul 30;120:73-88. doi: 10.1016/j.ejps.2018.04.040. Epub 2018 Apr 30.

PMID:
29719240
13.

Coexistence of MACC1 and NM23-H1 dysregulation and tumor budding promise early prognostic evidence for recurrence risk of early-stage colon cancer.

Ozturk E, Aksoy SA, Ugras N, Tunca B, Ceylan S, Tezcan G, Yilmazlar T, Yerci O, Egeli U, Cecener G.

APMIS. 2018 Feb;126(2):99-108. doi: 10.1111/apm.12801.

PMID:
29700912
14.

Triple negative breast cancer: new therapeutic approaches and BRCA status.

Guney Eskiler G, Cecener G, Egeli U, Tunca B.

APMIS. 2018 May;126(5):371-379. doi: 10.1111/apm.12836. Review.

PMID:
29696717
15.

Overexpression of the Long Noncoding RNA HomeoboxA Transcript at the Distal Tip Predicts Poor Prognosis in a KRAS-Independent Manner in Periampullary Region Tumors.

Balcin O, Ak Aksoy S, Tunca B, Kaya E, Egeli U, Tezcan G, Ugras N, Cecener G, Isik O, Dundar HZ, Yerci O.

Pancreas. 2018 Feb;47(2):213-220. doi: 10.1097/MPA.0000000000000984.

PMID:
29329159
16.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

17.

Epigenetic approach to early-onset Parkinson's disease: low methylation status of SNCA and PARK2 promoter regions.

Eryilmaz IE, Cecener G, Erer S, Egeli U, Tunca B, Zarifoglu M, Elibol B, Bora Tokcaer A, Saka E, Demirkiran M, Akbostanci C, Dogu O, Colakoglu B, Kenangil G, Kaleagasi H.

Neurol Res. 2017 Nov;39(11):965-972. doi: 10.1080/01616412.2017.1368141. Epub 2017 Aug 22.

PMID:
28830306
18.

Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.

Tezcan G, Tunca B, Demirci H, Bekar A, Taskapilioglu MO, Kocaeli H, Egeli U, Cecener G, Tolunay S, Vatan O.

Nutr Cancer. 2017 Aug-Sep;69(6):873-880. doi: 10.1080/01635581.2017.1339810. Epub 2017 Jul 18.

PMID:
28718668
19.

Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro.

Tezcan G, Taskapilioglu MO, Tunca B, Bekar A, Demirci H, Kocaeli H, Aksoy SA, Egeli U, Cecener G, Tolunay S.

Biomed Pharmacother. 2017 Jun;90:713-723. doi: 10.1016/j.biopha.2017.04.022. Epub 2017 Apr 15.

PMID:
28419967
20.

Circulating miR-195 as a Therapeutic Biomarker in Turkish Breast Cancer Patients.

Cecene G, Ak S, Eskiler GG, Demirdogen E, Erturk E, Gokgoz S, Polatkan V, Egeli U, Tunca B, Tezcan G, Topal U, Tolunay S, Tasdelen I.

Asian Pac J Cancer Prev. 2016;17(9):4241-4246.

21.

Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.

Cecener G, Guney Eskiler G, Egeli U, Tunca B, Alemdar A, Gokgoz S, Tasdelen I.

Mol Biol Rep. 2016 Nov;43(11):1273-1284. Epub 2016 Aug 29.

PMID:
27573125
22.

An in vitro model for the development of acquired tamoxifen resistance.

Guney Eskiler G, Cecener G, Tunca B, Egeli U.

Cell Biol Toxicol. 2016 Dec;32(6):563-581. Epub 2016 Sep 1.

PMID:
27585693
23.

A novel [Mn2(μ-(C6H5)2CHCOO)2(bipy)4](bipy)(ClO4)2 complex loaded solid lipid nanoparticles: synthesis, characterization and in vitro cytotoxicity on MCF-7 breast cancer cells.

Guney Eskiler G, Cecener G, Dikmen G, Kani I, Egeli U, Tunca B.

J Microencapsul. 2016 Sep;33(6):575-584. Epub 2016 Sep 26.

PMID:
27575255
24.

Mutation analysis of the PARKIN, PINK1, DJ1, and SNCA genes in Turkish early-onset Parkinson's patients and genotype-phenotype correlations.

Erer S, Egeli U, Zarifoglu M, Tezcan G, Cecener G, Tunca B, Ak S, Demirdogen E, Kenangil G, Kaleagası H, Dogu O, Saka E, Elibol B.

Clin Neurol Neurosurg. 2016 Sep;148:147-53. doi: 10.1016/j.clineuro.2016.07.005. Epub 2016 Jul 4.

PMID:
27455133
25.

Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response.

Atasayar G, Eryilmaz IE, Karli N, Egeli U, Zarifoglu M, Cecener G, Taskapilioglu O, Tunca B, Yildirim O, Ak S, Tezcan G, Can FE.

J Neurol Sci. 2016 Jul 15;366:149-154. doi: 10.1016/j.jns.2016.05.019. Epub 2016 May 13.

PMID:
27288795
26.

Impact of 3'UTR variation patterns of the KRAS gene on the aggressiveness of pancreatobiliary tumors with the KRAS G13D mutation in a Turkish population.

Egeli U, Ak S, Cecener G, Tunca B, Tezcan G, Sevinc ED, Kaya E, Dundar HZ, Sarkut P, Ozen Y, Balcin O, Evrensel T, Yerci O, Ugras N.

Pancreatology. 2016 Jul-Aug;16(4):677-86. doi: 10.1016/j.pan.2016.05.004. Epub 2016 May 24.

PMID:
27256640
27.

Expression and clinical significance of miRNAs that may be associated with the FHIT gene in breast cancer.

Sevinc ED, Cecener G, Ak S, Tunca B, Egeli U, Gokgoz S, Tolunay S, Tasdelen I.

Gene. 2016 Sep 30;590(2):278-84. doi: 10.1016/j.gene.2016.05.033. Epub 2016 May 25.

PMID:
27236032
28.

miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation.

Egeli U, Tezcan G, Cecener G, Tunca B, Demirdogen Sevinc E, Kaya E, Ak S, Dundar HZ, Sarkut P, Ugras N, Yerci O, Ozen Y, Evrensel T.

Pancreas. 2016 Oct;45(9):1294-302. doi: 10.1097/MPA.0000000000000640.

PMID:
27101576
29.

Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer.

Tezcan G, Tunca B, Ak S, Cecener G, Egeli U.

World J Gastrointest Oncol. 2016 Jan 15;8(1):83-98. doi: 10.4251/wjgo.v8.i1.83. Review.

30.

The Anticancer Activity of Complex [Cu2(μ-(C6H5)2CHCOO)3(bipy)2)] (ClO4) -Solid Lipid Nanoparticles on MCF-7 Cells.

Kani I, Dikmen G, Eskiler GG, Cecener G, Tunca B, Egeli U.

Curr Drug Deliv. 2016;13(8):1339-1350.

PMID:
26750100
31.

Effects of EGFR, CK19, CK20 and Survinin gene expression on radiotherapy results in patients with locally advanced head and neck cancer.

Kekilli KE, Abakay CD, Tezcan G, Tunca B, Egeli U, Saraydaroglu O, Esbah O, Ekinci AS, Arslan S, Uslu N, Ozkan L.

Asian Pac J Cancer Prev. 2015;16(7):3023-7.

32.

Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients.

Sevinc ED, Egeli U, Cecener G, Tezcan G, Tunca B, Gokgoz S, Tasdelen I, Tolunay S, Evrensel T.

Asian Pac J Cancer Prev. 2015;16(1):291-7.

33.

BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.

Erturk E, Cecener G, Tezcan G, Egeli U, Tunca B, Gokgoz S, Tolunay S, Tasdelen I.

Gene. 2015 Feb 10;556(2):163-9. doi: 10.1016/j.gene.2014.11.047. Epub 2014 Nov 22.

PMID:
25445393
34.

Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer.

Erturk E, Cecener G, Polatkan V, Gokgoz S, Egeli U, Tunca B, Tezcan G, Demirdogen E, Ak S, Tasdelen I.

Asian Pac J Cancer Prev. 2014;15(19):8319-24.

35.

Olea europaea leaf extract improves the treatment response of GBM stem cells by modulating miRNA expression.

Tezcan G, Tunca B, Bekar A, Budak F, Sahin S, Cecener G, Egeli U, Taskapılıoglu MO, Kocaeli H, Tolunay S, Malyer H, Demir C, Tumen G.

Am J Cancer Res. 2014 Sep 6;4(5):572-90. eCollection 2014.

36.

Ficus carica latex prevents invasion through induction of let-7d expression in GBM cell lines.

Tezcan G, Tunca B, Bekar A, Yalcin M, Sahin S, Budak F, Cecener G, Egeli U, Demir C, Guvenc G, Yilmaz G, Erkan LG, Malyer H, Taskapilioglu MO, Evrensel T, Bilir A.

Cell Mol Neurobiol. 2015 Mar;35(2):175-87. doi: 10.1007/s10571-014-0109-y. Epub 2014 Sep 12.

PMID:
25212824
37.

Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations.

Erturk E, Cecener G, Egeli U, Tunca B, Tezcan G, Gokgoz S, Tolunay S, Tasdelen I.

Mol Cell Biochem. 2014 Oct;395(1-2):77-88. doi: 10.1007/s11010-014-2113-4. Epub 2014 Jun 19.

PMID:
24942235
38.

BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients.

Cecener G, Egeli U, Tunca B, Erturk E, Ak S, Gokgoz S, Tasdelen I, Tezcan G, Demirdogen E, Bayram N, Avci N, Evrensel T.

Cancer Invest. 2014 Oct;32(8):375-87. doi: 10.3109/07357907.2014.919302. Epub 2014 Jun 2.

PMID:
24884828
39.

Molecular markers for patients with thymic malignancies: not feasible at present?

Avci N, Cecener G, Deligonul A, Erturk E, Tunca B, Egeli U, Tezcan G, Akyildiz EU, Bayram AS, Gebitekin C, Kurt E, Evrensel T.

Asian Pac J Cancer Prev. 2014;15(8):3457-60.

40.

MicroRNA expression patterns of tumors in early-onset colorectal cancer patients.

Ak S, Tunca B, Tezcan G, Cecener G, Egeli U, Yilmazlar T, Ozturk E, Yerci O.

J Surg Res. 2014 Sep;191(1):113-22. doi: 10.1016/j.jss.2014.03.057. Epub 2014 Mar 24.

PMID:
24746948
41.

microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.

Tezcan G, Tunca B, Bekar A, Preusser M, Berghoff AS, Egeli U, Cecener G, Ricken G, Budak F, Taskapılıoglu MO, Kocaeli H, Tolunay S.

Cell Mol Neurobiol. 2014 Jul;34(5):679-92. doi: 10.1007/s10571-014-0050-0. Epub 2014 Apr 2.

PMID:
24691539
42.

Microsatellite instability status affects gene expression profiles in early onset colorectal cancer patients.

Ak S, Tunca B, Yilmazlar T, Tezcan G, Cecener G, Egeli U, Ozturk E, Yerci O, Ertürk E, Zorluoglu A.

J Surg Res. 2013 Dec;185(2):626-37. doi: 10.1016/j.jss.2013.07.014. Epub 2013 Jul 31.

PMID:
23992855
43.

Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients.

Tunca B, Tezcan G, Cecener G, Egeli U, Zorluoglu A, Yilmazlar T, Ak S, Yerci O, Ozturk E, Umut G, Evrensel T.

J Cancer Res Clin Oncol. 2013 Apr;139(4):691-702. doi: 10.1007/s00432-013-1372-x. Epub 2013 Jan 16.

PMID:
23322277
44.

Olea europaea leaf extract alters microRNA expression in human glioblastoma cells.

Tunca B, Tezcan G, Cecener G, Egeli U, Ak S, Malyer H, Tumen G, Bilir A.

J Cancer Res Clin Oncol. 2012 Nov;138(11):1831-44. doi: 10.1007/s00432-012-1261-8. Epub 2012 Jun 22.

PMID:
22722712
45.

CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer.

Tunca B, Egeli U, Cecener G, Tezcan G, Gökgöz S, Tasdelen I, Bayram N, Tolunay S, Umut G, Demirdogen E, Erturk E, Ak S, Cetintas S, Evrensel T.

Tumori. 2012 Mar-Apr;98(2):243-51. doi: 10.1700/1088.11937.

PMID:
22677992
46.

The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma.

Cecener G, Tunca B, Egeli U, Bekar A, Tezcan G, Erturk E, Bayram N, Tolunay S.

Cell Mol Neurobiol. 2012 Mar;32(2):237-44. doi: 10.1007/s10571-011-9753-7. Epub 2011 Sep 18.

PMID:
21928112
47.

Analysis of mismatch repair gene mutations in Turkish HNPCC patients.

Tunca B, Pedroni M, Cecener G, Egeli U, Borsi E, Zorluoglu A, Di Gregorio C, Yilmazlar T, Yerci O, de Leon MP.

Fam Cancer. 2010 Sep;9(3):365-76. doi: 10.1007/s10689-010-9336-7.

PMID:
20373145
48.

FHIT gene sequence variants and reduced Fhit protein expression in glioblastoma multiforme.

Cecener G, Tunca B, Egeli U, Bekar A, Guler G, Tolunay S, Aksoy K.

Cell Mol Neurobiol. 2010 Mar;30(2):301-7. doi: 10.1007/s10571-009-9452-9. Epub 2009 Sep 17.

PMID:
19760177
49.

Investigation of MMAC/PTEN gene mutations and protein expression in low grade gliomas.

Cecener G, Tunca B, Egeli U, Bekar A, Guler G, Vatan O, Tolunay S.

Cell Mol Neurobiol. 2009 Jul;29(5):733-8. doi: 10.1007/s10571-009-9397-z. Epub 2009 Apr 7.

PMID:
19350382
50.

Mutation analysis of the FHIT gene in bronchoscopic specimens from patients with suspected lung cancer.

Cecener G, Tunca B, Egeli U, Karadag M, Vatan O, Uzaslan E, Tolunay S.

Tumori. 2008 Nov-Dec;94(6):845-8.

PMID:
19267103

Supplemental Content

Support Center